Esteso Paul, Gauvreau Kimberlee, Milligan Caitlin, Vo Linda, Fynn-Thompson Francis, Blume Elizabeth D, Singh Tajinder P
Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts.
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
JAMA Netw Open. 2025 Apr 1;8(4):e257766. doi: 10.1001/jamanetworkopen.2025.7766.
Older children awaiting a heart transplant (HT) sometimes receive a heart offer from a donor with a history of drug use (HDU). The effect of using such donor hearts on posttransplant survival in pediatric recipients is unclear.
To assess the association of using hearts from donors with HDU on posttransplant graft survival in pediatric HT recipients.
DESIGN, SETTING, AND PARTICIPANTS: For this retrospective cohort study, all pediatric HT recipients (aged <18 years) in the Organ Procurement and Transplantation Network database during January 1, 2000, to December 31, 2020, were identified. Among the recipients who received a heart from a donor with HDU, nearly all donors were aged 11 years or older. A propensity score (PS) model was developed to assess the probability of receiving a heart from a donor with HDU using baseline recipient and donor variables, limiting the study cohort to donors aged 11 years or older. Data were analyzed from October 2023 to November 2024.
HT using a heart from a donor with HDU (exposure group) vs from a donor without HDU (control group).
The main outcome was graft loss (death or retransplant) assessed at 90 days after transplant and long term among 90-day survivors. Kaplan-Meier survival curves and a Cox proportional hazards regression model that accounted for matching of exposure and control groups were used to compare risk of graft loss.
This study included 2730 pediatric HT recipients. Their median age at HT was 14 years (IQR, 11-16 years), and most (1642 [60.1%]) were male. Overall, the exposure group comprised 822 children who received a heart from a donor with HDU; of these, 765 (93.1%) were PS matched to the control group. There was no difference in risk of graft loss within 90 days (hazard ratio [HR], 0.93 [95% CI, 0.55-1.57]; P = .78) or at long-term follow-up (HR, 1.04 [95% CI, 0.87-1.25]; P = .68) between PS-matched groups. Risk of graft loss within 90 days was not significantly different in children who received a heart from a donor with a history of cocaine use (157 pairs) vs children in the control group (HR, 0.55 [95% CI, 0.19-1.54]; P = .25); however, the risk of long-term graft loss among 90-day survivors was significantly higher (HR, 2.03 [95% CI, 1.35-3.06]; P = .001).
In this cohort study of pediatric HT recipients, there was no association of 90-day graft survival with donor HDU; however, donor history of cocaine use was associated with a higher risk of long-term graft loss. These findings may be important when considering a donor with HDU for pediatric HT candidates.
等待心脏移植(HT)的大龄儿童有时会收到有药物使用史(HDU)的供体提供的心脏。使用此类供体心脏对儿科受者移植后存活的影响尚不清楚。
评估使用有HDU的供体心脏与儿科HT受者移植后移植物存活之间的关联。
设计、设置和参与者:在这项回顾性队列研究中,确定了2000年1月1日至2020年12月31日期间器官获取与移植网络数据库中的所有儿科HT受者(年龄<18岁)。在接受有HDU供体心脏的受者中,几乎所有供体年龄均在11岁或以上。开发了倾向评分(PS)模型,以使用基线受者和供体变量评估接受有HDU供体心脏的概率,将研究队列限制为11岁或以上的供体。数据于2023年10月至2024年11月进行分析。
使用有HDU供体的心脏进行HT(暴露组)与使用无HDU供体的心脏进行HT(对照组)。
主要结局是在移植后90天评估的移植物丢失(死亡或再次移植)以及90天存活者中的长期移植物丢失。使用Kaplan-Meier生存曲线和考虑了暴露组与对照组匹配情况的Cox比例风险回归模型来比较移植物丢失风险。
本研究纳入了2730名儿科HT受者。他们接受HT时的中位年龄为14岁(四分位间距,11 - 16岁),大多数(1642例[60.1%])为男性。总体而言,暴露组包括822名接受有HDU供体心脏的儿童;其中,765名(93.1%)与对照组进行了PS匹配。PS匹配组之间在90天内(风险比[HR],0.93[95%置信区间,0.55 - 1.57];P = 0.78)或长期随访时(HR,1.04[95%置信区间,0.87 - 1.25];P = 0.68)的移植物丢失风险无差异。接受有可卡因使用史供体心脏的儿童(157对)与对照组儿童相比,90天内的移植物丢失风险无显著差异(HR,0.55[95%置信区间,0.19 - 1.54];P = 0.25);然而,90天存活者中的长期移植物丢失风险显著更高(HR,2.03[95%置信区间,1.35 - 3.06];P = 0.001)。
在这项关于儿科HT受者的队列研究中,90天移植物存活与供体HDU无关联;然而,供体的可卡因使用史与长期移植物丢失风险较高相关。在考虑为儿科HT候选者使用有HDU的供体时,这些发现可能很重要。